Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vibostolimab + pembrolizumab + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous (vibostolimab, Pembrolizumab, Oxaliplatin), Oral (capecitabine)
01
Overview
This is an investigational **combination regimen** of four drugs: **vibostolimab**, an anti-TIGIT monoclonal antibody that blocks TIGIT-mediated immunosuppression and activates T cells; **pembrolizumab**, an anti-PD-1 monoclonal antibody checkpoint inhibitor that boosts T cell anti-tumor activity; **capecitabine**, a small molecule oral prodrug of 5-fluorouracil (5-FU) used as a chemotherapy agent; and **oxaliplatin**, a platinum-based chemotherapeutic agent that crosslinks DNA and induces tumor cell death. This combination is being studied in clinical trials for the treatment of solid tumors, with ongoing evaluation primarily in non-small cell lung cancer and potentially other tumor types[1][3][7].
- Brand names
- KEYTRUDA (pembrolizumab)Xeloda (capecitabine)Eloxatin (oxaliplatin)
- Other names
- vibostolimab + pembrolizumab + capecitabine + oxaliplatin
02
Targets
TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)DNATIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on vibostolimab + pembrolizumab + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vibostolimab + pembrolizumab + capecitabine + oxaliplatin.